Last viewed: AZN


Prices are updated after-hours



nasdaq:AZN Astrazeneca PLC

AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (4.8% 1m) (13.6% 1y) (0.0% 2d) (0.6% 3d) (2.6% 7d) (NaN% volume)
http://astrazeneca.com
Sec Filling | Patents | 70600 employees

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

add to today's watch list email alert is off




cardiovascular   respiratory   urea   renal   metabolic  

Press-releases


Tendinitis Treatment Market to grow at a CAGR of 6.79% by 2026 |Evolving Opportunities with Abbott Laboratories and Alvogen ehf | 17000+ Technavio Reports
Published: 2022-01-19 (Crawled : 07:00) - prnewswire.com
GLAXF | News | $22.5865 | twitter stocktwits trandingview |
Health Technology
| | O: -1.71% H: 0.22% C: -1.8%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.59% H: 0.0% C: 0.0%
GSK | News | $45.96 | twitter stocktwits trandingview |
Health Technology
| | O: -0.84% H: 0.0% C: 0.0%
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: -0.26% H: 0.83% C: 0.83%
ABT | News | $126.83 | twitter stocktwits trandingview |
Health Technology
| | O: -0.7% H: 0.0% C: 0.0%

treatment report
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-01-17 (Crawled : 09:00) - biospace.com/
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology

enhertu granted positive cancer breast cancer
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Published: 2022-01-14 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: -0.21% H: 0.98% C: 0.98%
INCY | $74.78 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.0% C: 0.0%
ONCY | News | $1.55 | twitter stocktwits trandingview |
Health Technology
| | O: 0.65% H: 0.0% C: 0.0%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.17% H: 0.0% C: 0.0%
PFE | News | $53.68 | twitter stocktwits trandingview |
Health Technology
| | O: -1.01% H: 0.0% C: 0.0%

treatment cancer breast cancer merge
PD-1 And PD-L1 Inhibitors Market to Grow by USD 29.97 billion| Reduction in Cancer Mortality Rate to Boost Market Growth | 17,000+ Technavio Research Reports
Published: 2022-01-13 (Crawled : 11:00) - prnewswire.com
AGEN | $2.84 | twitter stocktwits trandingview |
Health Technology
| | O: -2.28% H: 1.67% C: -3.67%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 1.0% H: 0.02% C: -0.99%
AMGN | News | $233.74 | twitter stocktwits trandingview |
Health Technology
| | O: -0.15% H: 0.0% C: 0.0%
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: 2.17% H: 0.07% C: -0.53%

research cancer growth
Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Published: 2022-01-12 (Crawled : 14:00) - globenewswire.com
ARTL | $0.4349 | twitter stocktwits trandingview |
Health Technology
| | O: 0.28% H: 2.47% C: 1.13%
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.76% C: -0.16%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 1.68% H: 0.0% C: 0.0%


Global Depression Drugs Market to Surpass US$ 15,379.0 Million by 2028, Says Coherent Market Insights
Published: 2022-01-07 (Crawled : 19:00) - prnewswire.com
PFE | News | $53.68 | twitter stocktwits trandingview |
Health Technology

AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology

SNYNF | News 2 d | $104.92 | twitter stocktwits trandingview |
Health Technology

TAK | $14.52 | twitter stocktwits trandingview |
Health Technology

SNY | News 2 d | $51.79 | twitter stocktwits trandingview |
Health Technology

LLY | News | $245.05 | twitter stocktwits trandingview |
Health Technology

GLAXF | News | $22.5865 | twitter stocktwits trandingview |
Health Technology

GSK | News | $45.96 | twitter stocktwits trandingview |
Health Technology

AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology

JNJ | News | $167.165 | twitter stocktwits trandingview |
Health Technology

drug depression
Integral Molecular Adds Transgenic Humanized Mice to Expand its MPS Antibody Discovery Platform Through a Partnership with Alloy Therapeutics
Published: 2022-01-05 (Crawled : 12:30) - prnewswire.com
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.16% H: 0.0% C: 0.0%
CNTX | $2.07 | twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 3.33% C: -7.78%

partnership era therapeutics molecular antibody platform
USD 105.55 Mn growth in Bile Duct Cancer Market | North America to Occupy 41% Market Share | Technavio
Published: 2022-01-05 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: 1.48% H: 0.0% C: -3.3%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.16% H: 0.0% C: 0.0%

cancer growth
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $119.67 | twitter stocktwits trandingview |
Health Technology
| | O: 2.49% H: 1.06% C: -2.49%
GNPX | $2.08 | twitter stocktwits trandingview |
Health Technology
| | O: 16.79% H: 0.0% C: 0.0%
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: 0.03% H: 0.17% C: 0.07%

keytruda fast track designation treatment fda fast track gene therapy era cel fda fast track lung cancer therapy cancer
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2021-12-23 (Crawled : 14:00) - biospace.com/
AZN | News | $59.69 | twitter stocktwits trandingview |
Health Technology
| | O: -1.0% H: 0.71% C: 0.24%

enhertu trial cel lung cancer cancer phase 3 initiated
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying